DK1771208T3 - Anvendelse af thioflavin radiomarkerede derivater i amyloid billeddannelse til vurdering af anti-amyloide terapier - Google Patents

Anvendelse af thioflavin radiomarkerede derivater i amyloid billeddannelse til vurdering af anti-amyloide terapier

Info

Publication number
DK1771208T3
DK1771208T3 DK05787557.7T DK05787557T DK1771208T3 DK 1771208 T3 DK1771208 T3 DK 1771208T3 DK 05787557 T DK05787557 T DK 05787557T DK 1771208 T3 DK1771208 T3 DK 1771208T3
Authority
DK
Denmark
Prior art keywords
amyloid
thioflavin
assessment
radio
image
Prior art date
Application number
DK05787557.7T
Other languages
English (en)
Inventor
William E Klunk
Chester A Mathis Jr
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of DK1771208T3 publication Critical patent/DK1771208T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK05787557.7T 2004-07-02 2005-07-01 Anvendelse af thioflavin radiomarkerede derivater i amyloid billeddannelse til vurdering af anti-amyloide terapier DK1771208T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58448704P 2004-07-02 2004-07-02
PCT/US2005/023617 WO2006014381A2 (en) 2004-07-02 2005-07-01 Use of thioflavin radiolabeled derivatives in amyloid imaging gor assessing anti-amyloid therapies

Publications (1)

Publication Number Publication Date
DK1771208T3 true DK1771208T3 (da) 2013-09-02

Family

ID=35504952

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05787557.7T DK1771208T3 (da) 2004-07-02 2005-07-01 Anvendelse af thioflavin radiomarkerede derivater i amyloid billeddannelse til vurdering af anti-amyloide terapier

Country Status (16)

Country Link
US (4) US8147798B2 (da)
EP (1) EP1771208B1 (da)
JP (1) JP2008505115A (da)
CN (2) CN101137397A (da)
AU (1) AU2005270026A1 (da)
BR (1) BRPI0512893B8 (da)
CA (2) CA2830939C (da)
CY (1) CY1114644T1 (da)
DK (1) DK1771208T3 (da)
ES (1) ES2427963T3 (da)
NO (1) NO339187B1 (da)
PL (1) PL1771208T3 (da)
PT (1) PT1771208E (da)
RU (1) RU2007104107A (da)
SI (1) SI1771208T1 (da)
WO (1) WO2006014381A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
PT1334091E (pt) * 2000-08-24 2013-01-07 Univ Pittsburgh Derivados de tioflavina e seu uso no diagnóstico e terapia da doença de alzheimer
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
JP2009508863A (ja) * 2005-09-16 2009-03-05 ユニバーシティー オブ ピッツバーグ 少なくとも１種のアミロイド形成タンパク質を含むアミロイド沈着物を検出するためのｉｎｖｉｖｏまたはｉｎｖｉｔｒｏ方法
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
PT2182983E (pt) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
MX2010002196A (es) * 2007-08-30 2010-03-18 Ge Healthcare Ltd Composicion radiofarmaceutica.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5603855B2 (ja) 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
CN102224423B (zh) 2008-09-23 2014-10-22 维斯塔实验室有限公司 聚集的τ分子的配体
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102272132A (zh) * 2008-11-06 2011-12-07 首尔大学教产学协力团 氟化苯并噻唑衍生物、其制备方法以及利用其用于诊断阿尔茨海默病的显像剂
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング
US20150157744A1 (en) * 2012-06-27 2015-06-11 Geoffrey B. Johnson Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
US9422286B2 (en) 2014-01-27 2016-08-23 Washington University Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease
AU2016308189B2 (en) * 2015-08-18 2021-03-11 The Regents Of The University Of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses
NZ746901A (en) * 2016-03-11 2023-06-30 Ac Immune Sa Bicyclic compounds for diagnosis and therapy
WO2021188592A1 (en) * 2020-03-16 2021-09-23 Emory University Radionuclide tracers of 1-amino-3,4-difluorocyclopentane-1-carboxylic acid, derivatives, and uses thereof
CN116953008B (zh) * 2023-06-14 2024-10-22 汕头大学医学院第二附属医院 基于磁共振成像的β淀粉样蛋白浓度检测方法及系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092003A1 (en) * 1999-12-29 2003-05-15 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of Alzheimer's disease
PT1334091E (pt) * 2000-08-24 2013-01-07 Univ Pittsburgh Derivados de tioflavina e seu uso no diagnóstico e terapia da doença de alzheimer
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO2002085903A2 (en) * 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
JP2005523903A (ja) * 2002-02-13 2005-08-11 アメルシャム・パブリック・リミテッド・カンパニー アミロイド斑の生体内撮像用のベンゾチアゾール誘導体
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
GB0307855D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
CN101060865B (zh) 2004-07-02 2011-10-05 匹兹堡大学高等教育联邦体系 诊断淀粉样蛋白沉积相关疾病的前驱形式的方法

Also Published As

Publication number Publication date
EP1771208B1 (en) 2013-06-19
WO2006014381A3 (en) 2007-01-18
EP1771208A2 (en) 2007-04-11
NO20070593L (no) 2007-03-27
CN101137397A (zh) 2008-03-05
ES2427963T3 (es) 2013-11-05
BRPI0512893A (pt) 2008-04-15
BRPI0512893B1 (pt) 2019-12-24
US8147798B2 (en) 2012-04-03
RU2007104107A (ru) 2008-08-10
CY1114644T1 (el) 2016-10-05
US20080219931A1 (en) 2008-09-11
CA2587248C (en) 2014-01-07
CN102973954A (zh) 2013-03-20
PL1771208T3 (pl) 2013-11-29
US8580229B2 (en) 2013-11-12
CA2830939A1 (en) 2006-02-09
WO2006014381A2 (en) 2006-02-09
PT1771208E (pt) 2013-09-24
US20140105820A1 (en) 2014-04-17
JP2008505115A (ja) 2008-02-21
CA2587248A1 (en) 2006-02-09
NO339187B1 (no) 2016-11-14
BRPI0512893B8 (pt) 2021-07-27
CA2830939C (en) 2017-02-28
US8343457B2 (en) 2013-01-01
US20120177572A1 (en) 2012-07-12
WO2006014381A9 (en) 2006-04-13
AU2005270026A1 (en) 2006-02-09
SI1771208T1 (sl) 2013-10-30
US20130045164A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
DK1771208T3 (da) Anvendelse af thioflavin radiomarkerede derivater i amyloid billeddannelse til vurdering af anti-amyloide terapier
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
DK2114531T3 (da) Punktpropper og fremgangsmåder til indgivelse af terapeutiske midler
LTC2213652I2 (lt) Stilbeno dariniai ir jų panaudojimas amiloido plokštelių surišimui ir vizualizacijai
DE602005027428D1 (de) Toner
PL1642616T3 (pl) Zintegrowana resuscytacja
DE602005007983D1 (de) Photoempfindliches Bildaufzeichnungselement
DE602004019389D1 (de) Toner
HUE036512T2 (hu) ATP-kötõ kazetta transzportereinek modulátorai
CY2013024I2 (el) Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
DK1945632T3 (da) Heterocycliske modulatorer af ATP-bindende kassettetransportører
EP1779444A4 (en) TUNABLE PHOTONIC CRYSTAL
NL300998I1 (nl) Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan
EP1945194A4 (en) DENTAL AND ENDODONTIC FILLING MATERIALS AND METHOD
DE602006001604D1 (de) Tragbares metrologisches Bildaufnahmegerät
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
DE602005005527D1 (de) Verschlussdüse
DK2086932T3 (da) Substituerede aryl-indol forbindelser og deres kynurenin/kynuramin-lignende metabolitter som terapeutiske midler
DK1948607T3 (da) Cyclopropylaminer med histamin-H3-receptormodulatorer
DE502005007052D1 (de) Sitzbefestigungsvorrichtung
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
DE602005023094D1 (de) Entwickler und Bilderzeugungsmethode
DE602005003608D1 (de) Bilderzeugende Materialien
DE602005019525D1 (de) Verschlussdüse